Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase ...

To date the trial has had no Severe Adverse Effect reported. The Phase I open label clinical research trial for KOA, registered with the U.S. National Institutes of Health under number NCT01809769 , tests the safety and efficacy of intra-articular injections of autologous haMPC in order to reduce inflammation and regenerate damaged joint tissues.

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Cellular-Biomedicine-Group-Achieves-50-Enrollment-/ArticleNewsFeed/Article/detail/813527?ref=25